Reviva Q1 net loss $7.4M; FDA alignment on brilaroxazine NDA path

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Net loss approximately $7.4M ($0.25 per share) for Q1 2024 vs $6.9M ($0.31 per share) for Q1 2023.
Cash $12.0M as of March 31, 2024, down from $23.4M at December 31, 2023.
FDA aligned on registrational Phase 3 program for brilaroxazine in schizophrenia; RECOVER-2 trial start expected Q2 2024.
Topline data from 1-year OLE trial expected Q4 2024; potential NDA submission targeted for Q4 2025.
Company initiated Phase 3 RECOVER-1 data presentations at SIRS and ASCPT meetings in Q1 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

REVIVA PHARMACEUTICALS HOLDINGS, INC. reported first quarter ended March 31, 2024 results: net income approximately $7.4 million, EPS $0.25 per share.

Period: first quarter ended March 31, 2024
Net income: approximately $7.4 million
EPS: $0.25 per share
Result: reported results

Exact text from the filing

The Company reported a net loss of approximately $7.4 million, or $0.25 per share, for the three months ended March 31, 2024

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

REVIVA PHARMACEUTICALS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-24-016364

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.